Ginkgo Bioworks (DNA) Expected to Announce Earnings on Thursday

Ginkgo Bioworks (NYSE:DNA) is anticipated to release its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect Ginkgo Bioworks to post earnings of ($1.80) per share and revenue of $37.5680 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Ginkgo Bioworks Trading Down 3.7%

Shares of Ginkgo Bioworks stock opened at $8.88 on Tuesday. Ginkgo Bioworks has a 12 month low of $5.00 and a 12 month high of $17.58. The firm has a market capitalization of $537.80 million, a P/E ratio of -1.42 and a beta of 1.55. The business has a fifty day simple moving average of $9.11 and a two-hundred day simple moving average of $10.64.

Analyst Ratings Changes

Several research firms recently issued reports on DNA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ginkgo Bioworks in a research report on Wednesday, January 21st. Wall Street Zen cut Ginkgo Bioworks from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Finally, TD Cowen lowered their price target on Ginkgo Bioworks from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. One investment analyst has rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Ginkgo Bioworks has a consensus rating of “Reduce” and an average price target of $10.50.

Institutional Investors Weigh In On Ginkgo Bioworks

A number of large investors have recently made changes to their positions in the company. The Manufacturers Life Insurance Company bought a new position in Ginkgo Bioworks in the 2nd quarter worth $226,000. Shay Capital LLC grew its holdings in Ginkgo Bioworks by 6.2% during the second quarter. Shay Capital LLC now owns 19,382 shares of the company’s stock valued at $218,000 after purchasing an additional 1,124 shares during the period. Numerai GP LLC increased its position in Ginkgo Bioworks by 94.1% in the fourth quarter. Numerai GP LLC now owns 25,625 shares of the company’s stock worth $213,000 after buying an additional 12,421 shares in the last quarter. PharVision Advisers LLC bought a new position in shares of Ginkgo Bioworks in the third quarter worth about $192,000. Finally, Public Employees Retirement System of Ohio bought a new position in shares of Ginkgo Bioworks in the fourth quarter worth about $170,000. 78.63% of the stock is currently owned by institutional investors.

About Ginkgo Bioworks

Ginkgo Bioworks, Inc is a synthetic biology company that designs custom microbes for customers across a range of industries. Utilizing a proprietary organism foundry platform, the company engineers cells to produce high-value chemicals, enzymes, and other biological materials. By integrating automation, data analytics and machine learning, Ginkgo Bioworks seeks to accelerate the development of biologically derived solutions at industrial scale.

The company’s services span the entire development cycle, from genetic design and strain optimization to fermentation and downstream processing.